Brain atrophy in cognitively impaired elderly: The importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial

American Journal of Clinical Nutrition

Volumn 102, Issue 1, 2015, Pages 215-221

  Jernerén, Fredrik ^a   Elshorbagy, Amany K ^a,b   Oulhaj, Abderrahim ^c   Smith, Stephen M ^a   Refsum, Helga ^a,d   Smith, A David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

B vitamin; Brain atrophy; Homocysteine; Mild cognitive impairment; 3

Indexed keywords

CREATININE; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FOLIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; PLACEBO; PYRIDOXINE; TRIACYLGLYCEROL; VITAMIN B COMPLEX;

AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ATROPHY; BLOOD; BODY MASS; BRAIN; COGNITIVE DEFECT; DIET SUPPLEMENTATION; NUTRITIONAL STATUS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ATROPHY; BODY MASS INDEX; BRAIN; COGNITION DISORDERS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NUTRITIONAL STATUS; RETROSPECTIVE STUDIES; VITAMIN B COMPLEX;

EID: 84937392787     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.114.103283     Document Type: Article

References (44)

1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, et al. Mild cognitive impairment. Lancet 2006;367:1262-70.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94.
3. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999;52: 1687-9.
4. Smith AD. Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci USA 2002;99:4135-7.
5. Jack CR Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600.
6. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009;6:347-61.
7. Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, Smith AD. Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol 2002;75:506-13.
8. Jack CR Jr., Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005;65:1227-31.
9. Huang TL. Omega-3 fatty acids, cognitive decline, and Alzheimer's disease: a critical review and evaluation of the literature. J Alzheimers Dis 2010;21:673-90.
10. Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health 2014;14:643.
11. Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, Debette S, Pikula A, Decarli C, Wolf PA, Vasan RS, et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012;78: 658-64.
12. Virtanen JK, Siscovick DS, Lemaitre RN, Longstreth WT, Spiegelman D, Rimm EB, King IB, Mozaffarian D. Circulating omega-3 polyunsaturated fatty acids and subclinical brain abnormalities on MRI in older adults: the cardiovascular health study. J Am Heart Assoc 2013;2: e000305.
13. Pottala JV, Yaffe K, Robinson JG, Espeland MA, Wallace R, Harris WS. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI Study. Neurology 2014;82: 435-42.
14. Samieri C, Maillard P, Crivello F, Proust-Lima C, Peuchant E, Helmer C, Amieva H, Allard M, Dartigues JF, Cunnane SC, et al. Plasma longchain omega-3 fatty acids and atrophy of the medial temporal lobe. Neurology 2012;79:642-50.
15. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 2012;6:CD005379.
16. Frautschy SA, Cole GM. What was lost in translation in the DHA trial is whom you should intend to treat. Alzheimers Res Ther 2011;3:2.
17. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 2011;7:412-7.
18. Smith AD. The worldwide challenge of the dementias: a role for B-vitamins and homocysteine? Food Nutr Bull 2008;29(2 Suppl): S143-72.
19. Vogiatzoglou A, Refsum H, Johnston C, Smith SM, Bradley KM, de Jager C, Budge MM, Smith AD. Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology 2008;71: 826-32.
20. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B-vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 2010;5:e12244.
21. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 2013;110: 9523-8.
22. Mehmetoglu I, Yerlikaya FH, Kurban S, Polat H. Plasma omega-3 fatty acid levels negatively and omega-6 fatty acid levels positively associated with other cardiovascular risk factors including homocysteine in severe obese subjects. Asia Pac J Clin Nutr 2012;21: 519-25.
23. Huang T, Zheng J, Chen Y, Yang B, Wahlqvist ML, Li D. High consumption of omega-3 polyunsaturated fatty acids decrease plasma homocysteine: a meta-analysis of randomized, placebo-controlled trials. Nutrition 2011;27:863-7.
24. Akesson B, Fehling C, Jägerstad M, Stenram U. Effect of experimental folate deficiency on lipid metabolism in liver and brain. Br J Nutr 1982; 47:505-20.
25. da Silva RP, Kelly KB, Al Rajabi A, Jacobs RL. Novel insights on interactions between folate and lipid metabolism. Biofactors 2014;40: 277-83.
26. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17: 479-89.
27. Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH. Longterm fatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. J Lipid Res 2010;51:2826-32.
28. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2012;27:592-600.
29. Witte AV, Kerti L, Hermannstadter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, Hahn A, Floel A. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex 2014; 24:3059-68.
30. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 2012;31:225-36.
31. Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF,Wieggers RL, Scheltens P, et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther 2013;5:59.
32. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Cognitive function after supplementation with B-vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU. FOL.OM3 randomized trial. Am J Clin Nutr 2011;94:278-86.
33. Polozova A, Gionfriddo E, Salem N Jr. Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins. Prostaglandins Leukot Essent Fatty Acids 2006;75:183-90.
34. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63:1545-50.
35. Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R, Smith N, Thambisetty M, Kloszewska I, Mecocci P, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 2014;35:271-8.
36. da Costa KA, Sanders LM, Fischer LM, Zeisel SH. Docosahexaenoic acid in plasma phosphatidylcholine may be a potential marker for in vivo phosphatidylethanolamine N-methyltransferase activity in humans. Am J Clin Nutr 2011;93:968-74.
37. Watkins SM, Zhu X, Zeisel SH. Phosphatidylethanolamine-Nmethyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J Nutr 2003;133: 3386-91.
38. Magret V, Elkhalil L, Nazih-Sanderson F, Martin F, Bourre JM, Fruchart JC, Delbart C. Entry of polyunsaturated fatty acids into the brain: evidence that high-density lipoprotein-induced methylation of phosphatidylethanolamine and phospholipase A2 are involved. Biochem J 1996;316:805-11.
39. Selley ML. A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging 2007;28:1834-9.
40. Miller RR, Leanza CM, Phillips EE, Blacquire KD. Homocysteineinduced changes in brain membrane composition correlate with increased brain caspase-3 activities and reduced chick embryo viability. Comp Biochem Physiol B Biochem Mol Biol 2003;136:521-32.
41. van Wijk N, Watkins CJ, Hageman RJ, Sijben JC, Kamphuis PG, Wurtman RJ, Broersen LM. Combined dietary folate, vitamin B-12, and vitamin B-6 intake influences plasma docosahexaenoic acid concentration in rats. Nutr Metab (Lond) 2012;9:49.
42. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr 2010;140:869-74.
43. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 2007;27:2751-9.
44. Kemse NG, Kale AA, Joshi SR. A combined supplementation of omega-3 fatty acids and micronutrients (folic acid, vitamin B12) reduces oxidative stress markers in a rat model of pregnancy induced hypertension. PLoS ONE 2014;9:e111902.